Patrick Coleman et al. Application No.: 09/515,014

Page 2

IN THE CLAIMS:

1. (Amended) A method for determining the presence of antibodies to HIV in a body fluid, comprising:

(a) contacting, under conditions which permit immunospecific binding to form a reaction mixture the body fluid with a composition containing at least one polypeptide or protein comprising the following amino acid sequences where oligopeptides having at least six amino acids which come within the sequence of at least one of the following polypeptide sequences will include epitopes within such sequence:

[(I) BRU124E (SEQ ID NO: 1)

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z]

(II) BRU124EX (SEQ ID NO: 2)

W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(III) BRU124F1X (SEQ ID NO: 3)

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Ile-Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z

(IV) BRU124F3X (SEQ ID NO: 4)

W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Ile-Gln-Asp-Asn-Y-Z

(V) ROD 124E1 (SEQ ID NO: 5)

A.

	PATRICK COLEMAN et al. Application No.: 09/515,014 Page 3	PATENT
35 36 37	W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe- Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly- Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z	
38		
39	(VI) ROD 124EX (SEQ ID NO: 6)	
40	W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-	
41	Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-	
42	Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-	
43 44	Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z	
45 46	(VII) ROD 124C2X (SEQ ID NO: 7)	
47	W-X-Lys-Leu-Lys-Asp-Phe-Arg-	
48	Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-	
49	Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-	
50	Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-	
51	Thr-Asp-Ile-Lys-Y-Z	
52	1111-Asp-110-Lys-1-Z	
53	(VIII) ROD 124C1X (SEQ ID NO: 8)	
54	W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-	
55	Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-	
56	Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-	
57	Thr-Asp-Ile-Lys-Y-Z	
58		
59	(IX) ROD 123C3X (SEQ ID NO: 9)	
60	X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-	
61	Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-	
62	Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-	
63	Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z	
64	· · · · · · · · · · · · · · · · · · ·	
65	(X) POL2A1 (SEQ ID NO: 10)	
66	W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-	
67	Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-	1. 11
68	Thr-Asp-Ile-Lys-Ile-Pro-Arg-Lys-	
	The risk has also he had highlightly	



PATENT

PATRICK COLEMAN et al. Application No.: 09/515,014 Page 4

 Ala-Lys-Ile-Ile-Y-Z

(XI) ROD124C5X (SEQ ID NO: 11)

ve-Len-Lve-Acn-Phe-Arg-Val-Tyr-Ph

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or an additional amino acid bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acid being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent or Cys; and Z is OH or NH₂. wherein W is either a H of the amino terminal NH₂ group of the polypeptide or an additional amino acid bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acid being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent or Cys; and Z is OH or NH₂.;

- (b) detecting whether immunospecific binding has occurred between the polypeptide and an antibody component of the body fluid in which an immune complex is formed and in which the detection of the immune complex indicates the presence of antibodies to HIV in the body fluid.
- 12. (Amended) A method for determining the presence of antibodies to HIV-1 in a body fluid, comprising:
- (a) contacting under conditions which permit immunospecific binding to form a reaction mixture the body fluid with a composition containing at least one polypeptide or protein comprising the following amino acid sequences where oligopeptides having at least six amino acids which come within the sequence of the following polypeptide sequence will include epitopes within such sequence:



		PATRICK COLEMAN et al. Application No.: 09/515,014 Page 5			
	9	[(I) BRU124E (SEQ ID NO: 1)			
	11 12 13 14	W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z]			
1	15	(II) BRU124EX (SEQ ID NO: 2)			
	16 17 18 19	W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-Phe-Arg- Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly- Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z			
	20	(III) BRU <u>124FX1</u> (SEQ ID NO: 3)			
	21 22 23 24 25	W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Ile-Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z			
	26	(IV) BRU124F3X (SEQ ID NO: 4)			
	27 28 29 30	W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Ile-Gln-Asp-Asn-Y-Z			
	31	wherein W is either a H of the amino terminal NH2 group of the polypeptide or			
	32	an additional amino acid bonded to the amino terminal NH2 group of the polypeptide, the			
	33	additional amino acid being selected to facilitate coupling of the polypeptide to a carrier			
N	34	protein or to a support; X is absent or Cys-Gly-Gly; Y is absent or Cys; and Z is OH or NH2;			
N	35	(b) determining whether immunospecific binding has occurred between the			
\	36	polypeptide and an antibody component of the body fluid in which the detection of			
	37	immunospecific binding indicates the presence of antibodies to HIV in the body fluid.			
* ** ** **	1	14. (Amended) A polypeptide composition, immunoreactive to antibodies to			
	2	HIV, comprising at least one of the following amino acid sequences:			
E S	3	[(I) BRU124E			

	PATRICK COLEMAN et al. Application No.: 09/515,014 Page 6	<u>PATENT</u>
4 5 6	W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-ProAla-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z]	
7		
8	(II) BRU124EX	
9 10 11	W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-GlnAsn-Phe-Arg- Val-Tyr-Tyr-Arg-Asp-Ser-Arg-AspPro-Leu-Trp-Lys-Gly- Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z	
12		
13	(III) BRU124F1X	
14 15 16 17	W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-ProAla-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Ile-Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z	
18		
19	(IV) BRU124F3X	
20 21 22	W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser- Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp- Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Y-Z	
23		
24	(V) ROD 124E1	
25 26 27	W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe- Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly- Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z	
28		
29	(VI) ROD 124EX	
30 31	W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys- Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-	



		PATRICK COLEMAN et al. Application No.: 09/515,014 Page 7	<u>TENT</u>
3	32 33	Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu- Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z	
	34		
	35	(VII) ROD 124C2X	
	36 37 38 39 40	W-X-Lys-Leu-Lys-Asp-Phe-Arg- Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu- Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys- Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly- Thr-Asp-Ile-Lys-Y-Z	
	41	(VIII) ROD 124C1X	
1	43 44 45 46	W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu- Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys- Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly- Thr-Asp-Ile-Lys-Y-Z	
	47		
	48	(IX) ROD 123C3X	
	49 50 51 52	X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe- Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly- Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly- Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z	
	53		
	54	(X) POL2A1	
	55 56 57 58	W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys- Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly- Thr-Asp-Ile-Lys-Ile-Pro-Arg-Arg-Lys- Ala-Lys-Ile-Ile-Y-Z	
	59		
	60	(XI) ROD124C5X	

•

•